Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Compounding topic
No spam. Unsubscribe anytime.
CRNA groups urge clarity after BRN signals compounding notification; board staff says pharmacy law controls
Summary
CRNA leaders told the BRN advisory committee they support the Board's patient-safety focus but urged clear guidance distinguishing immediate-use, point-of-care sterile compounding in anesthesia from commercial compounding in med spas; BRN staff said compounding rules stem from the Pharmacy Board and USP797, not a change in BRN law.
The CRNA Advisory Committee heard public comment from nurse-anesthetist leaders who asked the Board of Registered Nursing (BRN) to make clear how state compounding rules apply to anesthesia practice.
Dr. Kristen Roman, president of the California Association of Nurse Anesthesiology, told the committee that the BRN's March 26, 2026 notice regarding compounding by RNs and APRNs in "med spas and IV hydration clinics" risks conflating commercial compounding with the immediate-use, point-of-care sterile preparations routinely prepared by certified registered nurse anesthetists. "CRNAs routinely prepare compounded sterile preparations for immediate use as part of standard anesthesia care," Roman said, adding that the 2023 USP797 standards provide "clear evidence-based guidance" when such preparations are performed by trained clinicians.
Lori, BRN staff, responded that the BRN's recent action did not change statute and that compounding standards and enforcement rest with the Pharmacy Board and its regulations. Lori told the committee that state pharmacy rules allow limited immediate-use compounding for single-patient, life-or-limb-sparing situations and require use within a defined timeframe (noted in the meeting as within four hours). "RNs are still not able to compound" in a general sense, she said, "but CRNAs are able to compound up to three sterile medications for immediate use" under pharmacy-board guidelines.
Both speakers encouraged clearer, centralized guidance. Thomas Bachelor, secretary of CANA, urged the advisory committee to develop a public FAQ to address recurring confusion about scope and liability following AB876. BRN staff said they are willing to assemble or link to authoritative resources but cautioned that certain liability questions fall outside BRN jurisdiction.
Why it matters: immediate-use sterile compounding is part of many anesthesia workflows; unclear public communications about compounding could prompt misinterpretation by employers, facility credentialing committees, or outside clinicians. Clarifying whether point-of-care anesthesia compounding aligns with pharmacy regulations and USP797 is important to keep routine CRNA practice legally supported and to maintain patient safety.
What comes next: BRN staff offered to agendaize further discussion at a future meeting and invited stakeholders to submit suggested FAQ items and sample Q&A by email to the CRNA advisory mailbox. The committee did not take formal action on compounding during this meeting.
